Stockwinners Market Radar for August 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:23 EDT Cathie Wood's ARK Investment bought 198K shares of Butterfly Network today

19:25 EDT Comscore director buys $731K in common stock - In a regulatory filing, Comscore disclosed that its director Paul Livek bought 350K share of common stock on August 25th in a total transaction size of $731K.

18:57 EDT Peloton delays filing 10-K report - In a regulatory NT 10-K filing, the company states: "Peloton Interactive will not be able to timely file with the Securities and Exchange Commission its Annual Report on Form 10-K for the year ended June 30, 2022 for the reason set forth below. The Registrant requires additional time to permit completion of the accounting and disclosures related to the measurement of the Registrant's fourth quarter long-lived asset impairment charges associated with the Registrant's recent announcement to exit its last mile warehouses, including management's assessment of the effectiveness of internal controls over financial reporting as it relates to its accounts and disclosures related to these strategic business developments and for its registered public accounting firm, Ernst & Young LLP, to complete its necessary audit procedures over these matters. As a result, the Registrant is unable to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2022 by the prescribed due date without unreasonable effort or expense. The Registrant anticipates that the Annual Report will be filed as soon as practicable and prior to the fifteenth calendar day following the prescribed due date."

18:36 EDT 3M sets final exchange ratio in connection with Neogen transaction - 3M (MMM) "announced the final exchange ratio of 6.7713 for its split-off exchange offer to 3M stockholders to exchange their shares of 3M common stock for shares of common stock of Garden SpinCo Corporation. The exchange offer is being conducted in connection with the previously announced pending separation of 3M's food safety business and the subsequent merger of SpinCo, a subsidiary of 3M formed to hold the food safety business, with a subsidiary of Neogen Corporation (NEOG). For each share of 3M common stock that is validly tendered and accepted for exchange, 3M will deliver approximately 6.7713 shares of SpinCo common stock. Upon completion of the merger, each share of SpinCo common stock will be converted into the right to receive one share of Neogen common stock. As a result, 3M stockholders who tender shares of 3M common stock in the exchange offer will receive approximately 6.7713 shares of Neogen common stock for each share of 3M common stock accepted for exchange. Because the final exchange ratio is less than the upper limit, the upper limit is not in effect."

18:10 EDT Harmonic CFO Kalra sells 53,585 common shares - In a regulatory filing, Harmonic CFO Sanjay Kalra disclosed the sale of 53,585 common shares of the company on August 25 at a price of $11.358 per share.

17:59 EDT Snap introduces Dual Camera 'to capture multiple perspectives' - The Snap Team blogged, in part earlier, "Snap's Camera is one of the most used cameras in the world. Today, we're introducing Dual Camera, a new way for Snapchatters to capture multiple perspectives at the same time - so everyone can be part of the moment, as it happens.Open your Snapchat and you'll see a new icon in the camera toolbar. With one simple tap, you can start creating Snaps and Stories, or more polished Spotlight videos, with double the perspective. Dual Camera is a creative way for our community to capture exciting moments while being part of the memory - like rocking out at a music festival, or everyday moments like your culinary adventures in the kitchen Dual Camera has four layouts including vertical, horizontal, picture in picture, and cutout. Snapchatters can also add beloved Snapchat creative tools, including music, Stickers and Lenses. Dual Camera will be available globally on iOS today, with Android support in the coming months." Reference Link

17:48 EDT Meta Platforms' WhatsApp and JioMart in India partner on grocery shopping - Meta Platforms CEO Mark Zuckerberg posted earlier: "Excited to launch our partnership with JioMart in India. This is our first-ever end-to-end shopping experience on WhatsApp -- people can now buy groceries from JioMart right in a chat. Business messaging is an area with real momentum and chat-based experiences like this will be the go-to way people and businesses communicate in the years to come." On its blog the company added: The launch is part of a strategic partnership between Meta and Jio Platforms to accelerate India's digital transformation and provide people and businesses of all sizes opportunities to connect in new ways, fueling economic growth in the country. The JioMart on WhatsApp experience will revolutionize the way millions of businesses across India connect with their consumers while bringing unparalleled simplicity and convenience to people's shopping experience. People in India can start shopping on JioMart via WhatsApp by simply sending 'Hi' to the JioMart number on WhatsApp." Reference Link

17:22 EDT Gran Tierra to buy back up to 36M shares through normal course issuer bid - Gran Tierra Energy announces that the Toronto Stock Exchange has approved its notice of intention to make a normal course issuer bid for its shares of common stock. As of August 22, there were 368,871,685 Shares issued and outstanding and the public float was 360,339,690 Shares. Pursuant to the Bid, Gran Tierra will be able to purchase for cancellation up to 36,033,969 Shares, representing 10% of the public float, at prevailing market prices at the time of purchase, through the facilities of the TSX or alternative trading platforms in Canada, if eligible, or by such other means as may be permitted by the TSX, for a one year period commencing on September 1 and ending on August 31, 2023. Gran Tierra may purchase up to 514,658 Shares on the TSX during any trading day, which represents approximately 25% of 2,058,635, which represents the average daily trading volume on the TSX for the most recently completed six calendar months prior to the TSX's acceptance of the notice of the Bid. Gran Tierra may effect repurchases from time to time in the open market; provided that the aggregate purchase price under the Bid shall not exceed USD$37.5M without further consideration of and approval by Gran Tierra's board of directors. Management of Gran Tierra believes that the Shares, at times, have been trading in a price range which does not adequately reflect their value in relation to Gran Tierra's current operations, growth prospects and financial position. At such times, the purchase of Shares for cancellation or to satisfy awards granted under Gran Tierra's 2007 Equity Incentive Plan may be advantageous to stockholders by increasing the value of the Shares.

17:15 EDT Raytheon Technologies subsidiary awarded $176.98M Air Force contract - Rockwell Collins, a subsidiary of Raytheon Technologies, has been awarded a $176.98M firm-fixed-price, indefinite-delivery/indefinite-quantity contract for High Frequency Global Communications System, or HFGCS, - Scope Command Next Generation. This contract supports a ground radio equipment/network infrastructure and associated antenna subsystems in support of strategic military command and control communications. Work is expected to be completed by Aug. 30, 2028. This award is the result of a sole source acquisition. Air Force is the contracting activity.

17:14 EDT Officer of J.M. Smucker Knudsen sells $435K in company shares - Officer of JM Smucker Jeannette Knudsen disclosed in a regulatory filing that she had sold 3,042 shares of company stock at $143.03 per share on August 25, for a total transaction value of $435,097.

17:09 EDT Equity Bank to sell Cordell branch to High Plains Bank - Equity Bank, a subsidiary of Equity Bancshares, announced its entry into a definitive purchase and assumption agreement with High Plains Bank of Okeene, Oklahoma, with High Plains acquiring certain assets and assuming deposits of Equity's bank location in Cordell, Oklahoma. High Plains and Equity anticipate completing the acquisition by December 31, 2022. "Our focus as a community bank is our customers, and doing what is right for our communities, businesses, and families in our regions," said Brad Elliott, Chairman and CEO of Equity. "This includes working with strong community banks to ensure that local bank locations continue to appeal to and reflect the customers they serve. We believe we've found a leadership and customer service team as well as a trusted brand that will continue to serve our customers in Cordell for the long term." Equity's Cordell location has approximately $20 million in deposits. Following completion of the agreement, Equity and High Plains will work together with local team members, customers, and the community to ensure a seamless transition for customers. After closing of the agreement, High Plains' Cordell market will include approximately $35 million in deposits, ranking No. 5 in Washita County, Oklahoma, according to FDIC Market Share data from S&P Global. The purchase and assumption of the Cordell location is subject to regulatory approval and satisfaction of customary closing conditions.

16:44 EDT International Game, DoubleDown agree in principle to settle legal proceedings - International Game (IGT) and DoubleDown Interactive (DDI) announced an agreement in principle to settle the Benson v. DoubleDown Interactive LLC, et. al. lawsuit and associated proceedings. IGT completed the sale of DoubleDown Interactive, the operator of social gaming business DoubleDown Casino, to DoubleU Diamond LLC, a subsidiary of DoubleDown, in June 2017. The agreement in principle, entered into by certain subsidiaries of IGT and DoubleDown, remains contingent on final court approval by the U.S. Federal District Court for the Western District of Washington. Under the terms of the settlement, which take effect only after final court approval of the proposed class settlement: A total of $415M will be paid into a settlement fund of which IGT's subsidiaries will contribute $269.75M and DDI will contribute $145.25M. All members of the nationwide settlement class who do not exclude themselves will release all claims relating to the subject matter of the lawsuit. Subject to final court approval of the settlement of the Benson v. DoubleDown Interactive LLC, et. al. lawsuit, IGT and DoubleDown have also resolved all indemnification and other claims between themselves and their respective subsidiaries and affiliates relating to the Benson Matters. As a result of the settlement agreement, IGT will accrue a $119.75M non-operating expense in the third quarter related to the incremental loss associated with the Benson Matters and related claims between IGT and DoubleDown and their respective subsidiaries and affiliates.

16:28 EDT Wabash adds two dealers to North American dealer network - Wabash announced it has added two dealers to its North American dealer network. Two of the largest dealers in the Northeast, Bergey's Truck Centers and Allegiance Trucks, will be full line dealers of Wabash parts, services and equipment, including dry and refrigerated van trailers, dry and refrigerated truck bodies and platform trailers. Allegiance Trucks offers new and used medium- to heavy-duty trucks, parts, and services, providing a one-stop solution to address customer needs, reduce downtime and keep trucks on the road. Allegiance Trucks will be representing Wabash in Maine, Vermont, New Hampshire, Massachusetts, Connecticut, Rhode Island as well as parts of New York and New Jersey. Bergey's is a company operating 15 truck centers and eight truck parts locations across Pennsylvania, Maryland, Delaware and New Jersey, as well as a heavy-duty parts warehouse in Telford, Pennsylvania. In addition, Bergey's also operates 10 automotive dealership locations, extending their commercial offerings to include automotive and light duty pick-up trucks and vans.

16:19 EDT Caleres names Jack Calandra as new CFO - Caleres "announced that Jack Calandra, has been appointed senior vice president and CFO, effective September 12, 2022. Following the previously announced CEO succession, Calandra will succeed Ken Hannah, who has served as CFO of Caleres for the last seven years. Hannah will be available to Caleres as needed to support this orderly transition."

16:16 EDT TeraWulf announces amendments to Nautilus JV agreement with Talen - TeraWulf announced that the company subsidiary of Talen Energy Corporation have reached an agreement to amend their existing joint venture agreement for the Nautilus Cryptomine bitcoin mining facility, which is located adjacent to, and will source zero-carbon nuclear power directly from, Talen's 2.5 GW Susquehanna Station in Pennsylvania. The Nautilus Cryptomine Facility benefits from one of the lowest electricity costs among publicly traded bitcoin mining peers in the United States with contracted power for the first 100 MW of gross mining capacity at $0.02 per kilowatt hour for an initial term of five years. Under the amendments, TeraWulf will maintain the benefit of its previous share of 50 MW of the Initial Block at $0.02 per kilowatt hour. TeraWulf's affiliate, Beowulf Electricity & Data Inc., will continue to operate the Nautilus Cryptomine facility pursuant to its previously announced facility services agreement. Under the amended agreement, TeraWulf will retain a thirty-three percent ownership interest in the Nautilus JV. The Nautilus Cryptomine Facility has access to up to 300 MW of mining capacity from the Susquehanna Station, with each of the JV members having the right to increase digital infrastructure capacity at the site by 50 MW beyond the initial 200 MW planned. The Nautilus Cryptomine Facility is expected to be the first bitcoin mining facility site powered by 100% "behind the meter" zero-carbon nuclear energy. The Nautilus Cryptomine Facility remains on track to commence mining operations in Q4 2022.

16:08 EDT Timber Pharmaceuticals receives deficiency letter from NYSE American - Timber Pharmaceuticals announced that it had received a deficiency letter from NYSE American stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide. The Letter stated that because the Company's common stock had been trading for a low price per share for a substantial period of time, the Company was not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff determined that the Company's continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time or effecting a reverse stock split of its common stock, which the staff determined to be until February 23, 2023, which could be extended to the Company's next annual meeting of stockholders to be held in 2023. The Company intends to regain compliance with the NYSE American's continued listing standards by undertaking a measure or measures that are for the best interests of the Company and its stockholders.

16:03 EDT Alpine Acquisition announces extension request for merger agreement - Alpine Acquisition announced that its sponsor, Alpine Acquisition Sponsor, requested that the company extend the date by which it has to consummate a business combination from September 2 to December 2. The extension is the first of up to two three-month extensions permitted under the company's governing documents. In connection with such Extension, the Sponsor has notified the company that it intends to cause an aggregate of $1.07M to be deposited into the company's trust account established in connection with the company's initial public offering on or before September 2. As previously announced, the company entered into an agreement and plan of merger with AAC Merger Sub and Two Bit Circus. The transaction is expected to close in the fourth quarter of 2022, subject to the satisfaction of customary closing conditions, including the approval of the company's stockholders.

15:42 EDT Advanced Drainage to invest $65M in Ohio expansion - Advanced Drainage announced plans to invest a total of approximately $65M in Hilliard, Ohio, near the company's existing headquarters. This investment will fund the development of a nearly 110,000-square-foot industry-leading Engineering & Technology Center. The company plans to break ground in October at a 17-acre site at Lyman Drive and Davidson Road. The site is located west of ADS' Trueman Blvd. headquarters and will have a frontage on I-270. Barbour said the new facility is expected to open in late 2023. The Ohio Tax Credit Authority also announced it will provide ADS with tax credit assistance to continue the company's expansion in Hilliard. In return, the company must invest at least $10.8M into the project, retain 322 existing jobs currently in Hilliard, and create 200 new jobs that would result in $20M of new payroll to the state. All told, ADS plans to invest approximately $65M in construction and equipment for the new engineering center.

14:59 EDT BioCryst treatment of fibrodysplasia ossificans progressiva gets orphan status - BioCryst's treatment of fibrodysplasia ossificans progressiva was granted FDA orphan status, according to a post to the agency's website. Reference Link

14:01 EDT Cabaletta Bio provides update on DesCAARTes trial - Cabaletta Bio announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology, or EADV, Congress, which is being held virtually and in person in Milan, Italy from September 7-10. "Based on the evaluation of emerging data in cohorts A4 and A5, which will be presented at the EADV Congress, and subject to the finalization of the study protocol, as applicable, Cabaletta plans to prioritize initiation of the cohort in the combination sub-study (2.5 billion cells in addition to patient pre-treatment with intravenous immunoglobulin and cyclophosphamide) relative to its other additional planned cohort, cohort A6m (multi-dose regimen at 10 to 15 billion total cells)," the company stated. "The totality of the data generated to date from the DesCAARTes trial has provided important insights that have guided our efforts to enhance in vivo DSG3-CAART exposure. We believe that the prioritization of a planned combination cohort with intravenous immunoglobulin and cyclophosphamide administered prior to DSG3-CAART infusion represents a preferred approach to potentially further increase DSG3-CAART exposure and activity, which we believe may generate clinical responses in patients with mPV," added David Chang, M.D., Chief Medical Officer of Cabaletta. Additional information, including the EADV abstract as submitted in July 2022, can be found [here]:[https://www.cabalettabio.com/technology/posters-publications].

13:52 EDT Walmart says FTC lawsuit 'egregious' agency 'overreach,' asks for dismissal - Walmart issued the following statement about asking for federal court dismissal of the FTC's lawsuit Regarding Walmart Money Transfer Services: "The FTC's lawsuit is an egregious instance of agency overreach.The FTC is trying to hold Walmart liable for the criminal actions of completely unrelated third-party fraudsters, in spite of Walmart's extensive efforts to prevent those very fraudsters from defrauding our customers, and despite the FTC's lack of constitutional or statutory authority to bring the lawsuit. Walmart is now-and always has been-dedicated to its customers, and shares the FTC's goal of protecting customers from fraudsters." Reference Link

13:09 EDT RF Acquisition receives non-compliance notice from Nasdaq - RF Acquisition Corp. announced that on August 23, 2022 it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2022 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Global Market. Under Nasdaq rules, the Company has 60 calendar days, or until October 24, 2022, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q, or until February 20, 2023, to regain compliance.

12:00 EDT Getty Images falls -17.0% - Getty Images is down -17.0%, or -$4.58 to $22.35.

12:00 EDT Cameco rises 8.1% - Cameco is up 8.1%, or $2.17 to $28.82.

12:00 EDT Hill International rises 20.0% - Hill International is up 20.0%, or 56c to $3.36.

11:52 EDT Saia LTL Freight opens new terminal in Franklin Park, Illinois - Saia announced that Saia LTL Freight has opened a new terminal in Franklin Park, Illinois. Saia is enhancing its operations in the Chicago market by opening this latest facility in an important transportation hub. The terminal will be the carrier's fifth location in the Chicagoland area and the third facility it has opened in the state just this year. The new terminal is the largest facility Saia has opened to date this year. With 100 employees, substantial investments were made to modernize the terminal, which will support the local economy through jobs and by providing transportation services to hundreds of shippers operating throughout the customer-dense region. Beyond this opening, there are additional terminals slated to open across the Midwest through the year end.

11:22 EDT Veracyte reports new data published in 'Nature Medicine' on tumor pre-treatment - Veracyte announced that new data published today in Nature Medicine that the company said provides "the first evidence that the pre-treatment tumor microenvironment can impact response to chimeric-antigen-receptor T-cell therapy among patients with large B-cell lymphoma," or LBCL. "The study findings demonstrated for the first time the prognostic and predictive capabilities of Veracyte's proprietary biomarkers among LBCL patients treated with CAR T-cell therapy... Results published today suggest that the pre-treatment tumor immune contexture was associated with, and potentially a major determinant of, clinical outcomes in ZUMA-1 patients. Improved clinical outcomes were more associated with high resolution pre-treatment immune contexture characterized by Immunoscore CR and Immunosign 21 rather than with general T-cell gene profiles and densities," Veracyte stated. "These findings suggest that our offerings can help provide key insights into the mechanism of action for immuno-therapies such as CAR T-cell treatment. We believe our extensive capabilities and expertise in immuno-oncology position us well to serve biopharma companies that are developing cutting-edge treatments such as CAR T-cell therapies, immune checkpoint inhibitors and others," added Corinne Danan, general manager for Veracyte's Biopharma business unit.

11:15 EDT AMMO responds, disagrees with many of Steve Urvan's assertions - AMMO, Inc. responded to the letter and comments made by Steve Urvan, with the company's board providing the following statement: "AMMO's Board and management team are focused on executing on our strategy to drive long-term shareholder value. We disagree with many of the assertions and analysis contained in the public comments from Mr. Urvan and will be providing additional information for our shareholders in coming days and weeks. In the meantime, the Board and management team remain committed to ensuring AMMO is operated for the benefit of all its shareholders. We continue to invite all shareholders and other stakeholders to share with us their views and perspectives on these topics."

11:07 EDT FDA issues safety communication on Philips BiPAP machine recall - The Food and Drug Administration is alerting patients, caregivers, and health care providers that Philips Respironics recalled certain bi-level positive airway pressure machines that may contain a plastic contaminated with a non-compatible material. If that plastic is in the device motor, it may release certain chemicals of concern called volatile organic compounds, the agency said in a statement. The plastic may also cause the machine to fail and stop working suddenly during use, it adds. This recall is not associated with the PE-PUR foam issue impacting certain BiPAP machines recalled in June 2021. Philips distributed 386 affected BiPAP machines in the U.S. between August 6, 2020, and September 1, 2021. Reference Link

10:47 EDT Chimerix awarded BARDA contract for TEMBEXA - Chimerix announced that is has signed a multi-year contract with the Biomedical Advanced Research and Development Authority in the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response, for the delivery of up to 1.7M treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government. The contract 75A50122C00047, includes an initial product procurement of 319,000 treatment courses for approximately $115M. The 10-year contract, which contains options for future procurements, is valued at approximately $551M in total if BARDA elects to exercise all options. In addition to product procurement, the contract supports post-marketing activities of approximately $13M, for a total potential contract value of up to $680M. In May, Chimerix entered into an agreement with Emergent BioSolutions, Inc. (EBS) for the sale of worldwide rights to TEMBEXA for $225M upfront and potential additional milestones of up to $100M. Based on the terms of the final BARDA agreement, EBS is expected to pay Chimerix Upfront payment of $238M upon the signing of the pre-novation agreement; Potential milestone payments of up to $124M; 15% royalty on gross profit from sales of TEMBEXA outside the U.S.; 20% royalty on gross profit from sales of TEMBEXA in the U.S. that are in excess of 1.7M treatment courses; and Up to an additional $12.5M upon achievement of certain developmental milestones. Closing of the Transaction remains subject to BARDA's approval of a pre-novation agreement between Chimerix and EBS.

10:33 EDT Discover announces Advanced Analytics Resource Cnter - Discover announced its new Advanced Analytics Resource Center and welcomed its first cohort of 75 employees at its downtown Chicago Office called the 606. The launch of the AARC@606 advances Discover's investment in technology and analytics as well as its commitment to bringing jobs to Chicago. The program is designed to accelerate learning and career development, providing each employee the opportunity to rotate through a variety of projects and gain exposure to different areas of the business. During the program, employees will begin to specialize in a chosen area and eventually be transferred to a permanent role in that department. The company plans to grow the program with an additional cohort of 75-100 employees in 2023 with an opportunity to hire more based on the program's success.

10:01 EDT Gray Television adopts minimum wage of $18 per hour - Gray Television announced a new minimum wage of $18 per hour across the company. The new policy will become effective on October 1, 2022, for essentially all full-time, non-commissioned and non-contracted employees of Gray and its wholly owned subsidiaries. Roughly 2,000 employees will receive a raise as a result of this new policy.

10:00 EDT Getty Images falls -9.0% - Getty Images is down -9.0%, or -$2.42 to $24.51.

10:00 EDT JZ Stock trading resumes

10:00 EDT NexGen Energy rises 8.6% - NexGen Energy is up 8.6%, or 35c to $4.44.

09:55 EDT JZ Stock trading halted, volatility trading pause

09:49 EDT Helix Acquisition Corp trading halted, volatility trading pause

09:47 EDT Catalent falls -5.8% - Catalent is down -5.8%, or -$5.79 to $93.91.

09:47 EDT Geo Group rises 6.0% - Geo Group is up 6.0%, or 49c to $8.63.

09:47 EDT Hill International rises 20.0% - Hill International is up 20.0%, or 56c to $3.36.

09:23 EDT Grindrod Shipping enters exclusive discussions with Taylor Maritime on proposal - Grindrod Shipping Holdings made the following announcement. The Board of Directors of Grindrod Shipping Holdings refers to the Schedule 13D filed with the U.S. Securities and Exchange Commission, by Taylor Maritime Investment on August 29, 2022 in relation to the non-binding indicative proposal by TMI to acquire the entire issued and to be issued share capital of the Company not already owned by TMI, or a subsidiary or affiliate thereof, for an aggregate cash consideration of US$26.00 per share, by means of a tender offer, at a cash purchase price of US$21.00 per share to be paid in conjunction with a special cash dividend from the Company of US$5.00 per share to the shareholders of the Company. The Board wishes to inform that, following discussions with TMI in connection with the Board's consideration of strategic alternatives, the Company has entered into exclusive discussions with TMI regarding the Proposed Transaction; however, definitive terms for the Proposed Transaction have not been agreed upon between the parties. There is no certainty that any transaction will result from these discussions. Except to the extent required by the Singapore Code on Take-overs and Mergers and applicable U.S. securities laws, the Company does not intend to make further announcements in relation to its discussions with TMI unless and until the Company and TMI enter into a definitive agreement with respect to the Proposed Transaction.

09:22 EDT Grindrod Shipping says TMI offered to acquire all shares for $26 per share

09:18 EDT TriCo Bancshares raises quarterly dividend 20% to 30c per share - The Board of Directors of TriCo Bancshares declared a quarterly cash dividend of 30c per share on its common stock, no par value on August 25. This represents a $0.05 or 20% increase to the previous quarterly dividend. The dividend is payable on September 23 to holders of record on September 9.

09:17 EDT CareCloud starts deploying CareCloud Wellness offering - CareCloud has begun deploying its new CareCloud Wellness offering for chronic care management to a variety of clients. Since the start of Q2 2022, clients in 12 states, including New York, Washington and Florida, and in nine different practice specialties, ranging from internal medicine, endocrinology to behavioral health have signed up for CareCloud Wellness. Clients utilize CareCloud Wellness to provide software-enabled, CCM services to patients through CareCloud's expanding suite of digital health solutions to help providers enhance patient care and revenue streams.

09:16 EDT Entravision enters strategic partnership with LATV Networks - Entravision announced a strategic partnership with LATV Networks, a minority-owned and operated media company serving the Latino community as a content hub, talent incubator and cultural advocate.

09:09 EDT Medical Properties announces LifePoint to acquire interest in Springstone - Medical Properties Trust announced that a subsidiary of LifePoint Health has agreed to acquire a majority interest in Springstone Health Opco from the current management group based on an enterprise value of $250M. In October 2021, MPT invested approximately $190M, primarily in the form of a loan, and received a minority equity interest in Springstone in conjunction with its $760M acquisition of 18 behavioral hospitals. Pursuant to the LifePoint transaction's expected first half of 2023 closing, MPT expects to be paid approximately $200M in full satisfaction of the loan and will retain its minority equity interest, providing continued opportunity for MPT shareholders to participate in further value creation. MPT will continue to own and lease Springstone's behavioral hospitals. Furthermore, in order to align MPT more completely with its operations, LifePoint has agreed to extend by five years to 2041 the maturity of its existing master lease of eight general acute hospitals.

09:08 EDT Magellan Midstream to expand refined products pipeline system to El Paso - Magellan Midstream Partners announced that following a successful open season, the company plans to expand our refined petroleum products pipeline system from the Houston area to El Paso, Texas. Based on significant customer interest, Magellan is expanding our operating capabilities to El Paso to a new capacity of approximately 100,000 bpd. The expanded capacity will be accomplished by the construction of a new 16-inch, 30-mile pipeline along our existing route between Odessa and Crane, Texas and additional operational storage to facilitate incremental shipments. "Building on the 2020 expansion of our West Texas refined products pipeline system, Magellan is pleased to further expand our capabilities to El Paso, which serves as the gateway to a number of key demand centers that can benefit from our system's extensive optionality," said Aaron Milford, chief executive officer. "To meet strong market demand, we have increased the scope of this expansion to deliver essential fuels supported by take-or-pay commitments from quality customers, providing an attractive return for our investors." Magellan currently expects to spend approximately $125 million on this project, with the expanded capacity available early 2024, subject to receipt of all necessary permits and approvals.

09:04 EDT Capital Product Partners extends employment of two LNG carriers - Capital Product Partners announced the increase of the day rate for two of its LNG carriers, 'Aristarchos' and 'Asklipios', as well as the extension of the firm period by approximately 6.4 years to June and September 2031, respectively. In addition, the charterer was granted two options per vessel, each one for two years. As a result of the extension and the higher day rate, firm contracted revenues under the two charters increased from approximately $118.4 million to $485.7 million. The increased day rate will apply from September 1, 2022. The remaining charter duration for CPLP's fleet is now extended to 7.0 years from 6.2 as of June 30, 2022.

09:04 EDT AerCap signs lease agreements with Air Europa - AerCap announced it has signed lease agreements with Air Europa Lineas Aereas S.A.U. for the long-term lease of five Boeing 787-9 aircraft and ten Boeing 737-8 MAX aircraft. The aircraft are scheduled to deliver beginning in 2024 through 2026. Air Europa will become the first Spanish operator of the Boeing 737 MAX aircraft. "Air Europa has been a long-time friend and valued customer of AerCap. With this landmark transaction for the airline, we are delighted to reconfirm our belief in the Air Europa business and management team and wish them every success with their fleet modernization program," said Peter Anderson, Chief Commercial Officer, AerCap. "The future is bright for the Boeing 787 and MAX programs. For Air Europa these new technology fuel-efficient aircraft will provide improved cost efficiencies and help them to meet their sustainability commitments. We thank the team at Air Europa for the confidence they have placed in AerCap, and we look forward to working together as these aircraft deliver."

09:03 EDT Boeing announces UPS purchase of 8 additional 767s - Boeing (BA) announced an order from UPS (UPS) for eight more 767 Freighters. The incremental order will increase UPS's 767 Freighter fleet to 108 airplanes, enabling the global carrier to further modernize and sustainably grow its fleet. "This repeat order from UPS is a testament to the outstanding cargo capabilities of the 767 Freighter and further demonstrates Boeing's market leadership in the freighter segment," said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. "UPS will operate more than 100 767 Freighters with this order and will build its fleet of Boeing and Boeing-heritage airplanes to more than 260 airplanes. We are honored to play an important role in UPS's efforts to operate a more sustainable, more efficient fleet." UPS will begin taking delivery of these new airplanes in 2025, with an additional 767-300 Boeing Converted Freighter entering service in late 2023. This purchase builds on UPS's order for 19 767 Freighters in December 2021.

08:51 EDT NanoXplore acquires assets of XG Sciences, terms not disclosed - NanoXplore announced it was the winning bidder for a significant portion of the assets of XG Sciences in a sale conducted by XG's senior secured creditor pursuant to Article 9 of Michigan's enactment of the Uniform Commercial Code. NanoXplore and the senior creditor have entered into an asset purchase agreement pursuant to which NanoXplore is acquiring XG's mechanical milling platform, research and development lab and all issued and pending patents and trademarks, among other items. The payment of this transaction is paid in cash without any share issuance. Founded in 2006, XG Sciences specialized in the production of graphene nanoplatelets and the formulations of advanced materials that amplify product performance across diverse applications such as Lithium-ion battery anode materials, automotive, packaging, composites, concrete, and other industrial markets. The Company ceased operations in July. While operating, the Company worked with leading companies such as Ford for noise reduction and light-weighting using graphene-enhanced PU foam as well as Callaway Golf Company for graphene-enhanced golf balls. As a result of the transaction, NanoXplore now owns all patents and patent applications including a portfolio of 7 patents of silicon-graphene battery materials and all XG trademarks. NanoXplore is planning to move all the assets from Lansing, Michigan to Canada to establish a dedicated battery material R&D facility. Moreover, NanoXplore is planning to use these assets to build a silicon-graphene anode material facility with a production capacity of 100-200 tons per year during 2023.

08:49 EDT Cuentas, OLB Group surge after announcing licensing agreement - Shares of Cuentas (CUEN) are up 20% and those of OLB Group (OLB) are up 36% in pre-market trading as the two companies announce that they entered into a licensing and transaction sharing agreement and strategic collaboration.

08:46 EDT Fusion announces first patient dosed in Phase 1/2 study of FPI-1966 - Fusion Pharmaceuticals announced that the first patient has been dosed in the Phase 1/2 study evaluating [225Ac]-FPI-1966 in patients with advanced solid tumors expressing fibroblast growth factor receptor three. FPI-1966 utilizes Fusion's Fast-Clear linker to connect vofatamab, a human monoclonal antibody that targets FGFR3, with actinium-225. "Dosing of the first patient in this Phase 1/2 study of FPI-1966 demonstrates our continued ability to bring innovative targeted alpha therapies into the clinic," said Chief Executive Officer John Valliant, Ph.D. "This study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer target found in multiple tumor types with substantial unmet need, notably bladder, ovarian and head and neck cancers. FPI-1966, and the growing number of TATs in our pipeline, are designed as next generation antibody drug conjugates in that they leverage the potency of actinium-225 and alpha particle radiation in place of chemical toxins to selectively eradicate cancer cells. Given the prevalence of the FGFR3 target, and the use of a precision medicine approach that employs an imaging analogue to enable patient selection, we believe FPI-1966 has the potential to become an important new treatment paradigm for cancer patients." The Phase 1/2 multi-center, open-label clinical trial is designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics of FPI-1966 in patients with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumors. The study employs a 3 + 3 dose escalation design to evaluate multiple ascending doses of FPI-1966. The Phase 2 portion of the study will consist of two tumor-specific cohorts and one basket cohort.

08:43 EDT Camber Energy subsidiary files new patent application - Camber Energy's majority-owned subsidiary, Viking Energy Group announced that Viking's majority-owned subsidiary, Viking Protection Systems, filed on August 23, 2022 a new patent application in the United States Patent & Trademark Office relating to its electric transmission line protection technology. The patent application is a continuation of previous filings and covers systems for preventing ground faults in existing three phase electric transmission lines caused by line breakage. Fires caused by line breaks have caused injury, death and billions of dollars in damage to public and private property, to forests and to wildlife. Existing systems shut down the power on broken lines after the broken lines have contacted the ground and therefore do not always prevent faults that can cause disastrous damage. Viking Protection's rapid pro-active systems are designed to terminate the power before the broken line makes any contact with the ground, the aim being to prevent an incendiary event or other disaster. This new patent application is specific to systems that utilize Viking's high sensitivity parameter detection that reacts within fractions of a second to shut down broken lines before ground contact can occur.

08:40 EDT Atlantic Union Bank appoints Sherry Williams as CRO - Atlantic Union Bank (AUB) has named Sherry Williams as its new Chief Risk Officer. Williams will be responsible for the company's enterprise and regulatory risk management functions that serve to safeguard its customers, investors, reputation, and assets. Williams most recently held the position of Executive Vice President, Chief Risk Officer at Amalgamated Bank (AMAL) following several years as the Bank's Chief Auditor

08:38 EDT Neuronetics receivs 510(k) clearance of D-Tect MT Accessory - Neuronetics announced that they have received 510(k) clearance for their D-Tect MT Accessory, which is the latest innovation in NeuroStar's commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold mapping for treatment of major depressive disorder. D-Tect also allows the MT determination to be performed by only one person. The D-Tect MT Accessory will initially be available via a limited commercial launch, with a national rollout beginning in mid-September. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina.

08:38 EDT Exela signs non-binding LOI to create stand-alone European XBP platform - Exela Technologies announced that one of its subsidiaries entered into an exclusive non-binding letter of intent to form a stand-alone publicly listed company of its EMEA business, which has approximately $200M in annual revenue. The news follows the June 6 announcement in which Exela declared its intention to sell in excess of $200M of assets. The equity consideration of Exela's stake in the proposed transaction is valued at $220M. The cash to be injected into the EMEA business from the proposed transaction would be used for growth and general corporate purposes by the new, stand-alone Nasdaq listed European business. Completion of the transaction is subject to the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein, including regulatory and other approvals. Accordingly, there can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated. Readers are cautioned that those portions of the LOI that describe the proposed transaction, included the consideration to be issued therein, are non-binding. Exela only intends to announce additional details regarding the proposed transaction if and when a definitive agreement is executed.

08:36 EDT Kennedy Wilson director Zax buys 35,000 common shares - In a regulatory filing, Kennedy Wilson director Stanley Zax disclosed the purchase of 35,000 common shares of the company on August 26 at a price of $18.15 per share.

08:35 EDT Galecto announces publication on Galectin-3 in NSCLC patients - Galecto announced a recent publication in the Journal of Cancer Research and Clinical Oncology, a peer-reviewed scientific journal, supporting the Company's ongoing clinical programs by reinforcing the foundational galectin-3 biology underlying Galecto's approach to the inhibition of galectin-3 for the treatment of cancer. The journal article provides confirmation for the hypothesis that high levels of galectin-3 expression have a strong correlation with tumor resistance to checkpoint inhibitors. The publication includes study data from a group of patients with varying degrees of galectin-3 expression, with patients being categorized as having either "high" or "low" levels based on their blood galectin-3 levels. Patients in the high galectin-3 expression group showed significantly shorter overall survival and trends toward reduced progression-free survival when compared to patients in the low galectin-3 expression group. The Company believes that the inhibition of galectin-3 by GB1211, Galecto's selective oral small molecule candidate, could lead to an increase in the efficacy of checkpoint inhibitors in cancer patients with high galectin-3 expression. Preclinical data presented at the 2022 American Society of Clinical Oncology Annual Meeting in May 2022 showed that galectin-3 may be a key cause of resistance to checkpoint inhibitors. Further, it was shown that GB1211 reversed the galectin-3 induced blockage of the checkpoint inhibitors atezolizumab and pembrolizumab and increased the effects of these checkpoint inhibitors. GB1211 is currently being evaluated in combination with atezolizumab in a Phase 2a trial for the first-line treatment of non-small cell lung cancer.

08:34 EDT Ballard Power appoints Gradu as Chief Engineering Officer - Ballard Power Systems (BLDP) announced the appointment of Mircea Gradu, PhD, FSAE, as Chief Engineering Officer, CEngO, effective August 29th, 2022. Dr. Gradu most recently held the position of Senior Vice President, Automotive Programs at Velodyne Lidar (VLDR), a provider of smart lidar technology solutions for vehicle autonomy. As a member of the executive team, Dr. Gradu will collaborate with Dr. Kevin Colbow who serves as Ballard's Chief Technology Officer.

08:32 EDT NCS Multistage wins patent infringement case against TCO - NCS Multistage Holdings announced that a jury in the U.S. District Court for the Western District of Texas, Waco Division has found that an NCS patent, U.S. Patent No. 10,465,445, is valid and infringed by TCO AS's TDP-PO casing flotation device. The jury awarded NCS approximately $1.9M in past damages for infringement of the patent from late 2019. "We have secured another unanimous jury verdict protecting our AirLock casing buoyancy system technology from infringement," said Robert Nipper, NCS's CEO. "Our AirLock casing buoyancy system pioneered a new way to float casing in the wellbore and the jury verdict requires TCO to recognize the value of our patented innovation. NCS's portfolio of over 100 issued patents is the result of more than a decade of innovation and continuous improvement by NCS employees and considerable financial investment. We are grateful that a jury of our peers has once again affirmed those efforts by upholding the validity of the patent-in-suit. While our preference is to protect our intellectual property rights through resolution outside of court, we will continue to enforce our rights through the court system if they are not respected. This jury verdict reinforces our continuing drive to deliver innovative technologies that bring enhanced efficiency and value to our customers."

08:28 EDT Power Solutions appoints Kenneth Li as CFO - Power Solutions International, announced that Xun Kenneth Li has joined the Company as its CFO, effective August 29, 2022. Mr. Li succeeds Matthew Thomas, who has served as interim CFO. since April 2022. Mr. Thomas will resume his role as corporate controller. Most recently, Mr. Li served as CFO for ND Paper.

08:26 EDT Enlivex receives notice of allowance for Japenese patent on Allocetra - Enlivex Therapeutics announced that the Japanese Patent Office issued a Notice of Allowance for patent application number 2020-198242. Once issued, the resulting patent will provide Enlivex with added intellectual property protection through at least 2037, with claims covering the use of pooled donor cells as source materials for Allocetra. The Company expects that this new patent will be issued in Japan by the second quarter of 2023. Enlivex is developing Allocetra as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.

08:23 EDT iCAD says growing number of hospitals choos to adopt Breast AI suite - iCAD announced that a growing number of hospitals and imaging centers in the U.S. and Europe are increasingly choosing to adopt iCAD's Breast AI Suite, which includes ProFound AI, ProFound AI Risk, and PowerLook Density Assessment, via a subscription model. iCAD's subscription model offers an accelerated way for customers to adopt, deploy and scale the Company's technologies, with significantly lower up-front costs, compared to a one-time license sale. These models also offer customers the ability to add new functionalities more easily than in a one-time license sale model, and without costly capital outlays while driving long-term recurring revenue opportunities for the Company.

08:21 EDT Aemetis India plant selected to supply $41M of biodiesel - Aemetis announced that its Universal Biofuels subsidiary in India was selected by the three government-controlled oil marketing companies and a major oil refiner to supply approximately 8,000,000 gallons of biodiesel over the next two months. The combined revenues from the shipments are expected to be about $41 million and are scheduled to require the Aemetis biodiesel/glycerin production plant to operate near 100% capacity. About 70% of the diesel and gasoline in India is supplied by the OMCs, with the remaining fuel supplied by large non-government refineries. This volume of biodiesel to be supplied by Aemetis is expected to continue to occur in two-month bidding tenders on an ongoing basis to meet the requirements of the recently updated India National Biofuels Policy.

08:20 EDT Daxor CEO provides corporate update in shareholder letter - Daxor Corporation issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on form N-CSR on August 25, 2022, from CEO & President, Michael Feldschuh, which read in part, "Starting with the unaudited parent company results as of June 30, 2022, Daxor's net assets increased 35.3% to $19,615,712 or $4.85 per share as compared to $14,493,285, or $3.59 per share at June 30, 2021. Daxor's net assets decreased 7.3% to $19,615,712, or $4.85 per share as compared $21,152,719 or $5.24 per share at December 31, 2021 - however these numbers do not reflect any change of the valuation of the Operating Division at June 30, 2022. The valuation of the Operating Division remained at $16,500,000 at June 30, 2022, the same value as December 31, 2021 as the valuation of the Operating Division is traditionally performed on an annual basis at the conclusion of the fiscal year. For the six-month period ended June 30, 2022, Daxor had net dividend income of $130,943, net realized gains on investment activity of $1,370,610. There was a net decrease in the unrealized depreciation on investments, options and securities borrowed of $1,367,276 as we sold positions during the second quarter of 2022 prior period's significant unrealized gains unwound into realized gains for the period. Included in the Net Decrease in Net Assets Resulting from Operations of $1,812,497 is non-cash stock-based compensation expense of $275,490, in an effort to provide incentive to employees, officers, agents and consultants through proprietary interest in the company. There was a net realized loss of $1,535,071 from the operating division relating to spending on research, development, sales and overhead as the Company continues to invest judiciously in research and development for our 2022/2023 product launches, ramping the commercial sales teams, as well as production facilities for our next generation blood volume analyzers. Our net asset value has risen strongly in the last year and the operating business is experiencing exciting growth and development - increasing revenues from commercialization, great progress in research and development for our next-generation systems set to launch at the end of Q4 and beginning of Q1 2023, and the growing body of clinical evidence from leading research centers on the unique value of our diagnostic to save lives and vastly improve health and hospital economic outcomes. The opportunity for our business is to scale into the total serviceable market of more than ten million tests per year in the United States alone through organic growth, partnership, and joint ventures...The Company also reported that the number of Volumex diagnostic kits sold rose 49.4% in the first half of 2022 compared to the first half of 2021. Growth is being driven both by an increase in sales at existing accounts as well as acquisition of new accounts. The company feels that there are still substantial growth opportunities at existing accounts as there is room for growth from winning a higher percentage of patients within existing departments as well as expanding to other departments within the hospital where devices are present...The Company also continues to execute on its AIR FORCE/DOD SBIR Phase II contract which calls for the creation of our next generation non-isotopic tracer. This contract is slated for completion over the next several months and is on-track for successful completion based upon preliminary lab data collected to date. This novel fluorescing marker will extend new care settings beyond our current systems and complement existing product lines. Management anticipates that there will be significant interest and potential for uptake of the new systems based upon preliminary discussions with clinicians helping to develop the technology. Daxor's next generation devices will also be eligible for Phase III funding awards and acquisition by branches of the military for their deployment to aid in combat casualty care...The NIH has selected Daxor BVA-100 diagnostic as a metric to track patient health in its COVID long-hauler study in March of this year. This multi-year study will augment the existing data regarding volume derangement and COVID complications and add further to the Critical Care world's understanding of the virus and its impact on blood volume. The Company also announced in August 2021 that a promising research letter on the use of Daxor's BVA-100 analyzer on six COVID-19 patients at NYU Medical center had been published in the prestigious Journal of Critical Care. Daxor's prospective multi-center trial has completed enrollment of COVID patients, and the study has been expanded to include patients with sepsis as well. Management looks forward to sharing the results of the multi-center trial when they become available."

08:17 EDT AbbVie to present 23 abstracts at EADV Congress - AbbVie announced it will present 23 abstracts at the 31st European Academy of Dermatology and Venereology, EADV, Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in studies of difficult-to-treat patient populations, certain disease areas with few existing treatment options as well as real-world patient experience. Key data to be presented include: Late-breaking oral presentation of new data from the ongoing Phase 3 active psoriatic arthritis clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating long-term efficacy and safety, up to 100 weeks, in patients treated with SKYRIZI; Analyses from MEASURE-AD, a cross-sectional, 28-country, burden of disease study aimed to characterize global treatment patterns, healthcare resource utilization and costs, and the clinical and economic burden of moderate to severe atopic dermatitis; Results from VALUE, a 13-month interim analysis from a long-term, prospective observational study that has enrolled 2,700 patients from 21 countries, evaluating real-world efficacy, durability of response and time to first treatment change for moderate to severe psoriasis patients treated with SKYRIZI compared to other commonly used treatments; Results from aIMM, a Phase 3b, multicenter, interventional, open-label, single-arm study analyzing clinical efficacy, safety and quality-of-life outcomes after 16 weeks of treatment with SKYRIZI in psoriasis patients who previously achieved suboptimal responses to one of two IL-17 inhibitors, either secukinumab or ixekizumab; Interim analysis of the nearly 5-year LIMMitless open-label extension study evaluating long-term efficacy and safety data with continuous SKYRIZI treatment in patients with moderate to severe plaque psoriasis; Two real-world insurance claims database analyses examining economic and comorbidity impacts on patients with vitiligo.

08:14 EDT Lexagene Holdings verifies CDC monkeypox assay works on MiQLab System - LexaGene Holdings announces the System can perform the Centers for Disease Control and Prevention Monkeypox real-time PCR test. On July 23rd, the World Health Organization declared Monkeypox a public health emergency of international concern, and on August 4th, the United States government declared the epidemic a public health emergency. There is concern that back-to-school activities could result in a spike in infections.

08:11 EDT InnovAge appoints Kathy Andreasen as CPO - InnovAge Holding has named Kathy Andreasen as its Chief People Officer effective Aug. 29, 2022. Before joining InnovAge, she was the Chief Administrative and People Officer at Endurance International Group.

08:08 EDT Aeterna Zentaris regains full rights to Macrilen in U.S., Canada - Aeterna Zentaris (AEZS) announced that Novo Nordisk Healthcare AG (NVO), has exercised its right to terminate the amended development and commercialization license agreement previously entered into between Aeterna's wholly-owned subsidiary and Novo for Macrilen, the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency. Following Novo's 270-day notice period, Aeterna will regain full U.S. and Canadian rights to the product. Under the terms of the Commercial License, Novo Nordisk will return the regulatory approvals, the intellectual property and provide certain other assistance in order to aid in an orderly transition of Macrilen rights to the Company. Until the end of that 270-day period, Commercial License requires Novo Nordisk to continue selling and promoting Macrilen in the U.S., and Novo Nordisk's financial support of the pivotal safety and efficacy DETECT-trial remains unchanged until the end of that notice period. Macimorelin has been marketed in the U.S. by Novo Nordisk under the trade name Macrilen. Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen in the U.S. and Canada. In light of Novo Nordisk's decision, Aeterna plans to engage in robust business development efforts to identify and secure a new development and commercialization partner.

08:07 EDT Cohn Robbins, Allwyn announce $260M financing commitment from PPF Group - Allwyn Entertainment and Cohn Robbins announced that PPF Group, which currently owns approximately 4M shares of CRHC, has agreed to purchase up to an additional 26M Allwyn shares at $10.00 per share in connection with the previously announced business combination between Allwyn and CRHC. In exchange for its commitment to provide the Backstop to support the Business Combination, PPF Group - an international investment firm with about EUR 42 billion in assets and operations in 25 countries - will receive up to an additional 4 million class B shares in Allwyn. If PPF Group purchases the maximum number of shares under the Backstop, it would become an approximately 4.99% shareholder in the combined entity. Messrs. Gary Cohn and Clifton Robbins, Co-Founders and Co-Chairmen of Cohn Robbins, stated, "We believe PPF Group's Backstop commitment is another resounding vote of confidence in Allwyn's opportunity to grow organically and inorganically in the attractive $300 billion global lottery industry from an investor which knows the business very well. We are proud to bring CRHC shareholders the ability to become owners of such a strong business as Allwyn."

08:06 EDT Dare Bioscience expects to complete enrollment in Phase 2b RESPOND study in Q4 - Dare Bioscience announced that, based on the results of an interim analysis to evaluate the relative magnitude of the treatment effect, they expect to complete enrollment in the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in 4Q-2022, allowing for a topline data announcement target of 2Q-2023. The interim analysis was conducted by an independent third-party statistical resource and both Dare and SST continue to remain blinded to results of the study by treatment group. The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder. Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 inhibitor, being developed as a first-in-category option for the treatment of FSAD. FSAD is the inability to reach or maintain a sufficient physical response to sexual stimulation and, of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men. Sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of ED in men. Unlike the oral formulations of PDE-5 inhibitors, Sildenafil Cream is designed to be applied locally to the vaginal tissue prior to sexual activity to facilitate vasodilation and increased blood flow directly to the genital tissue to improve the physical arousal response symptoms commonly associated with FSAD. Increasing blood flow to the genital tissue, as Sildenafil Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women. This is similar to the way ED medications work in men by directing blood flow to the genitals when taken prior to sexual activity. The Phase 2b RESPOND study evaluates Sildenafil Cream compared to a placebo cream in pre- and peri-menopausal women over the course of 12 weeks, in an at-home setting, following both a non-drug and placebo cream run-in period. The Phase 2b RESPOND study is a first of its kind Phase 2b study that includes patient reported outcome instruments to screen eligible women with FSAD and a number of primary, secondary, and exploratory PRO assessments to measure improvement in localized genital sensations of arousal and reduction in the distress that women experience with FSAD. There are no FDA-approved treatments for FSAD and thus there are no efficacy endpoints that have been previously validated in Phase 3 pivotal studies for potential treatments for FSAD. The RESPOND study is designed to test the sensitivity of several efficacy endpoints and their ability to determine a treatment effect of Sildenafil Cream compared to placebo to inform the ongoing development program. The independent third-party statistical resource was provided with unblinded data in order to determine the relative magnitude of the treatment effect to enable a determination of next steps with study enrollment and enrollment targets.

08:05 EDT IceCure Medical submits regulatory filing in Vietnam for approval of ProSense - IceCure Medical announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction, DMEC, of Vietnam's Ministry of Health for the ProSense System and accessories. The application covers indications including benign and malignant breast tumors, benign and malignant lung tumors, benign and malignant liver tumors, kidney cancer, ablation of cancerous or malignant tissue, musculoskeletal tumors, and other indications. "Asia is a significant market for ProSense and Vietnam is one of the fastest growing healthcare markets in the region. Having started the regulatory process in Vietnam, we anticipate high interest from potential distributors in the country," stated IceCure CEO, Eyal Shamir. "This comes on the heels of our recent successes in the region with Shanghai Medtronic Zhikang Medical Devices Co. Ltd. in China and Terumo in Japan, Singapore, and Thailand."

08:04 EDT Farmmi announces repeat order to Southwest Asia - Farmmi received another repeat customer's order for its popular dried Shiitake mushrooms. The customer will export the Shiitake mushrooms to Jordan. Yefang Zhang, Farmmi's Chairwoman and CEO, commented "We are starting to see more customers trying to secure product further out in time. This gives us added visibility and is helpful in managing our supply chain from production and processing through warehousing and fulfilment. We believe the catalyst for the forward planning is an offshoot of the current global water drought, which is expected to have a materially negative impact on tomatoes, grapes and other products, which we do not presently sell. For us, mushrooms are one of the lowest water intensive products, making them one of the most environmentally friendly crops farmers can grow. We expect to see people increasing substituting mushrooms into their diets and recipes, which will potentially provide added uplift for our sales."

08:03 EDT Portage Biotech sees cash runway potentially extending into 2024

07:49 EDT H World CEO says Omicron variant significantly affected China business - Jin Hui, CEO of H World commented: "During the second quarter, a large-scale outbreak of the Omicron variant in China again significantly affected our China business, especially in April and May due to the extensive lockdowns in various cities. However, with a gradual lifting of the lockdowns since late May 2022, our RevPAR started to recover and improved to 86% of the 2019 level in June 2022, and further improved to 90% of the 2019 level in July 2022. Although COVID has been affecting our business from time to time over the last two-and-a-half years, our long-term strategy remains intact. In order to further increase our hotel coverage and penetration rate in China, we need to move our organization and management closer to the local market. Therefore, in the second quarter, we established six regional headquarters and shifted from brand-based to regional-based organizational structure for our economy and midscale brands. By doing so, we believe we can become even closer to our local customers, franchisees, and employees, and create more value for all of them in a more efficient, agile, and precise manner. Moreover, localized management and operational capabilities would achieve better regional synergy and result in higher operational efficiency. Different from the approach we adopted for the economy and midscale segments, we are keeping our brand-based organizational structure unchanged for our upper-midscale and upscale brands due to the importance of differentiated brand positioning and a unique customer experience for each of our upper-midscale and upscale brands. Lastly, as we mentioned before, we will no longer develop soft brands in the economy segment in the future. We will accelerate our exit from this particular segment through retiring our existing hotels in the next one to two years, thereby continuously enhancing the overall quality of hotels in our network. It also closely aligns with our long-term 'Sustainable Quality Growth' strategy. In Europe, the DH business further improved in the second quarter with RevPAR recovering to 93% of the 2019 level. This upward trend continued in July. However, against the background of surging inflation in Europe and the resulting substantial increase in costs as well as uncertainties about the future development of COVID and energy supplies, a comprehensive cash flow improvement program remains critical. Therefore, DH's near-term focus will remain on efficiency improvements, renegotiation of further lease waivers, and personnel cost optimization."

07:44 EDT Bowman Consulting announced 'immediately accretive' Anchor Consultants purchase - Bowman Consulting Group announced the purchase of Anchor Consultants. Headquartered in Chadds Ford, Pennsylvania, Anchor specializes in the planning, inspection, design, environmental permitting, dredging engineering, and construction management of waterfront infrastructure along coastal and inland waterways throughout North America. Under the leadership of Ahmad Nadeem, PE, the company's founder, Anchor's experience ranges from industrial ports and harbors to urban waterfront development. On the industrial side, Anchor services facilities handling bulk materials and containerized freight. On the urban side, Anchor services commercial and mixed-use waterfront developments, ferry terminals, and recreational docks. Anchor has also worked on military port facilities and cruise terminals. "The acquisition of Anchor furthers our diversification initiative adding to our customer base that builds and maintains critical infrastructure," said Gary Bowman, CEO of Bowman. "Ports and harbors are a critical component of the nation's infrastructure and Anchor provides us with a solid platform from which to build our presence and market share in this growing space. Ahmad has built a great team of experienced marine engineers serving an impressive list of clients with a broad array of services. Their expertise in waterfront planning, design and engineering will enable us to provide these services to many of our current clients and gain immediate cross-selling opportunities for our client relationship managers." The Company expects the Anchor acquisition to initially contribute approximately $2.5M of annualized net service billing and be immediately accretive. The transaction was financed with a combination of cash and notes including an unsecured seller note and a convertible seller note with an $18.00 per share conversion option.

07:40 EDT Amesite, NAFEO enter collaboration to provide support to HBCUS - Amesite announces it has partnered with the National Association for Equal Opportunity in Higher Education to deliver a complete Enterprise Learning Community Environment for Historically Black Colleges and Universities. NAFEO's LCE will deliver everything from first outreach in learner enrollment to certificates of completion - in one streamlined system - allowing HBCUs to expand partnerships with business, academic, and community organizations to identify and address professional skills gaps, as well as support upskilling needs of expanding alumni markets. The best-in-class, AI-powered LCE will be offered to NAFEO's membership for their use in scaling learning programs with efficiency and effectiveness.

07:39 EDT Dyne Therapeutics appoints Francesco Bibbiani as SVP, head of development - Dyne Therapeutics (DYN) announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Bibbiani joins Dyne from Ultragenyx Pharmaceutical (RARE), where he served as vice president of global clinical development and oversaw all stages of the development for neuromuscular and neurology product candidate.

07:34 EDT Camping World to acquire Clear Creek RV Center dealerships in Washington - Camping World announced an agreement has been signed to acquire the Clear Creek RV Center dealerships located in Silverdale and Puyallup, Washington. The acquisition is anticipated to close in September. The Silverdale facility is located at 11572 Clear Creek Road NW, Silverdale, Washington and the Puyallup facility is located at 16625 Meridian E., Puyallup, Washington. Both locations will transition to the Camping World brand, increasing the total number of Camping World locations in the State of Washington to six. The SuperCenters will include a wide range of new and used RVs for sale from top manufacturers in addition to a full assortment of RV and outdoor products and accessories and RV service, maintenance, and repair.

07:33 EDT Ituran announces distribution of $3M dividend - Ituran Location and Control announced that the Board of Directors approved the distribution of a cash dividend in the amount of 14c per share, totaling approximately $3M. The dividend will be paid to shareholders of record as of September 29, 2022. The Company will pay the dividend out on October 13, 2022 net of taxes at the rate of 25%

07:26 EDT Graphite One announces results of its Pre-Feasibility Study of its project - Graphite One announces the results of its Pre-Feasibility Study of the Graphite One Project: Parallel strategy to simultaneously develop a commercial scale battery anode materials manufacturing facility in Washington State and the Graphite Creek Mine in Alaska. Manufacturing would begin with purchased materials until Alaska production is available; Pre-tax internal rate of return of 26.0%, using an 8% discount rate, with a net present value of $1.93 billion and a payback period of 4.6 years; Post-tax internal rate of return of 22.0%, using an 8% discount rate, with net present value of $1.36 billion and a payback period of 5.1 years, before accounting for tax credits enacted by the U.S. Inflation Reduction Act of 2022, effective December 31, 2022; Measured plus Indicated resources increased 197% over 2019 results. Inferred resources increased 177%. The Preliminary Feasibility Study of the Graphite One Project was prepared by JDS Energy & Mining with assistance from various independent technical consultants. The Graphite One Project is planned as an integrated business operation to produce lithium ion battery anode materials and other graphite products for the U.S domestic market on a commercial scale using primarily natural graphite from Alaska. The Project combines the operation of an advanced graphite manufacturing facility to be located in Washington State with the supply of natural flake graphite from the Company's proposed Graphite Creek Mine in Alaska. The resources associated with the Company's Alaska State mining claims were cited by the U.S. Geological Survey in January 2022 as America's largest natural graphite deposit1.

07:23 EDT Silicon Labs board of directors authorizes additional $200M share repurchase - Silicon Labs announced that its board of directors has increased the authorization for the repurchase of the company's common stock by $200M. Originally announced on July 27, 2022, the stock repurchase program is now authorized for a total of $450M.

07:20 EDT Panacea Financial announces partnership with AAP - Panacea Financial, a division of Primis Financial, has partnered with the American Academy of Periodontology, AAP, to provide preferred doctor-centric banking services to AAP members nationwide. Tyler Stafford, CFA, CEO and Co-Founder of Panacea said, "Periodontists deserve service that understands their unique and specific needs and Panacea Financial provides just that: custom-built banking for their practice or personal needs for Periodontists across the country, including those in training. Panacea Financial is proud to work with the AAP in their mission to support Periodontists nationwide."

07:14 EDT Axalta Coating appoints Bertsch to board of directors - Axalta Coating Systems (AXTA) announced that Jan Bertsch, former Senior Vice President and Chief Financial Officer for Owens-Illinois, now O-I Glass (OI), has been appointed to the company's Board of Directors as an independent director, effective September 13, 2022. She will serve on the Axalta Audit Committee. The Company also announced that Elizabeth Lempres is stepping down as a member of the Board, effective September 15, 2022. With the appointment of Bertsch and the departure of Lempres, Axalta's Board will be composed of eight directors, four of whom were appointed to the Board since the beginning of 2020.

07:13 EDT View Inc. selected for phase two of The Interlock - View announced its Smart Windows have been selected for phase two of The Interlock, a $750M mixed-use property being developed by SJC Ventures in the emerging West Midtown neighborhood of Atlanta, Georgia. At phase two of The Interlock, View Smart Windows will enclose all offices. The windows, which use artificial intelligence to automatically adjust in response to the sun, will maximize natural light and views of downtown West Midtown while ensuring thermal comfort and energy efficiency. Phase two of The Interlock is slated to open in early 2024 and will offer 275,000 square feet of commercial space and 180,000 square feet of creative office space, plus 670 beds for Georgia Tech student housing.

07:11 EDT Immuron CEO Steven Lydeamore to host investor webinar - Immuron Limited invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited, Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard Time.

07:09 EDT Else Nutrition announces its Canadian brick, mortar rollout began in August - Else Nutrition announces that it began its Canadian brick and mortar rollout in August 2022, through a partnership with Canadian owned retail chain London Drugs, headquartered in Richmond, British Columbia. Else's Plant-Based Nutrition for Toddlers and Kids Nutritional Shakes are on shelf and available for purchase in London Drugs stores and will be available in 73 stores across Western Canada. London Drugs will also soon be adding Else Nutrition products to their online store at LondonDrugs.com. "Launching our Canadian retail rollout with an outstanding partner such as London Drugs is an exciting, and strategically sound initiative for Else," said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "Entering the Canadian marketplace in Western Canada via London Drugs, introduces our brand to a vibrant and healthy-minded consumer-base in the West, while acting as a springboard into greater Canada," she continued.

07:07 EDT LGI Homes opens Carter's Retreat community in Nashville Market - LGI Homes announced the opening of a new community in the Nashville, Tennessee market, Carter's Retreat.

07:06 EDT OTC Markets Group welcomes United Bancshares to OTCQX - OTC Markets Group announced United Bancshares has qualified to trade on the OTCQX Best Market. United Bancshares, Inc. previously traded on NASDAQ.

07:05 EDT Else Nutrition begins Canadian B&M rollout via London Drugs partnership - ELSE NUTRITION HOLDINGS announces that it began its Canadian brick and mortar rollout in August 2022, through a partnership with Canadian owned retail chain London Drugs, headquartered in Richmond, British Columbia. Else's Plant-Based Nutrition for Toddlers and Kids Nutritional Shakes are on shelf and available for purchase in London Drugs stores and will be available in 73 stores across Western Canada. With pharmacy retail stores in 36 major markets throughout British Columbia, Alberta, Saskatchewan, and Manitoba, the partnership gives Else Nutrition ideal access to parents purchasing for their children. London Drugs will also soon be adding Else Nutrition products to their online store at LondonDrugs.com which will deepen the distribution relationship and expose Else Nutrition to additional London Drugs customers.

07:01 EDT Acorda Therapeutics enters Nepicastat license agreement with Asieris - Acorda Therapeutics announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7M based on the achievement of regulatory milestones. Acorda will also receive a royalty on future net sales. Nepicastat is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda's U.S. subsidiary, Biotie Therapies.

06:54 EDT Merck to present new data at ESMO 2022 Congress - Merck, known as MSD outside of the United States and Canada, announced that research spanning 16 different cancer types will be presented at the European Society for Medical Oncology, ESMO, Congress 2022 in Paris, France from Sept. 9-13. The breadth of data showcases the continued impact of Merck's portfolio of oncology medicines and the potential of Merck's innovative oncology pipeline. "We are proud to present longer-term survival data in patients with lung, ovarian, melanoma and head and neck cancers, as well as findings that reinforce the impact of our medicines in earlier stages of certain cancers and in new combinations," said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "Notably, we look forward to sharing five-year survival results from the pivotal KEYNOTE-189 study that has established the foundational role of KEYTRUDA in the first-line treatment setting for patients with metastatic nonsquamous non-small cell lung cancer, and results from EV-103/KEYNOTE-869, a study of KEYTRUDA in combination with the antibody-drug conjugate, enfortumab vedotin, in patients with locally advanced or metastatic urothelial cancer." Key Merck and collaborative data at ESMO 2022: Five-year overall survival data from the pivotal Phase 3 KEYNOTE-189 and KEYNOTE-407 trials evaluating KEYTRUDA in combination with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer; Seven-year OS data from the Phase 3 SOLO-1 trial evaluating maintenance LYNPARZA in patients with advanced BRCA-mutated ovarian cancer, following first-line platinum-based chemotherapy and final OS results from the Phase 3 PAOLA-1 trial evaluating maintenance LYNPARZA in combination with bevacizumab in patients with advanced ovarian cancer following first-line platinum-based chemotherapy and bevacizumab; First-time data from Cohort K of the Phase 1b/2 EV-103/KEYNOTE-869 trial evaluating PADCEV in combination with KEYTRUDA as first-line treatment for patients with cisplatin-ineligible unresectable locally advanced or metastatic urothelial cancer, which reported positive topline results for the primary endpoint of objective response rate earlier this year; First-time data from NCI-sponsored SWOG S1801, a Phase 2 study of neoadjuvant versus adjuvant KEYTRUDA for clinically detectable and resectable stage III to IV melanoma, to be featured in Presidential Symposium II.

06:51 EDT Crypto names fall in pre-market as bitcoin extends decline below $20,000 - Stocks levered to bitcoin prices continue to slide in pre-market trading as the cryptocurrency extended its decline below the $20,000 level over the weekend, hitting a six-week around 19,500 level. Bit Digital (BTBT) is down 3.4% at $1.41, Riot Blockchain (RIOT) is down 3.2% at $6.57, Marathon Digital (MARA) is down 4.7% at $10.82, MicroStrategy (MSTR) is down 4.5% at $238.00 and Coinbase Global (COIN) is down 2.9% at $64.81.

06:50 EDT Life Time Group CFO Thomas Bergmann to retire, Robert Houghton to succeed - Life Time Group announced that president and CFO, Thomas Bergmann, has decided to retire from the company on December 31. In conjunction with Bergmann's retirement, the company also announced that Robert Houghton has been named executive VP and CFO effective August 28. Bergmann relinquished his CFO role concurrent with Houghton's election and will remain president to support the transition through the end of 2022. Bergmann joined Life Time in February 2016 as president and CFO. His operational and financial leadership has played a central role in the company's continued expansion and growth, positioning Life Time well for the future. In addition to building a strong finance team, he also led significant equity and debt transactions for the company, including minority equity investments, multiple debt capital market transactions and the October 2021 initial public offering.

06:43 EDT Walmart looks to buy oustanding shares of Massmart for ZAR62 per share - Massmart released interim results and issued a cautionary announcement regarding a Potential Offer from Walmart to acquire the outstanding shares in Massmart that it does not already own. Total sales from continuing operations for the 26 weeks to 26 June 2022 of R38.1B represented an increase of 1.9%, with comparable store sales increasing by 4.3%. Gross margin from continuing operations decreased by 95bps to 19.6%, while total continuing operations expenses grew at 4.4%, well below inflation of 7.4%. Margin and inflationary pressure resulted in trading profit from continuing operations declining from R792.1M in the prior year period to R377.3M in this reporting period. Sales from online platforms grew by 50.0% compared to the prior year period and Gross Merchandise Value increased by 108.0% over the same period. Massmart has issued a detailed cautionary announcement that the Board of Directors of Massmart and the Board of Directors of Walmart Inc. have reached an in principle agreement regarding the terms and conditions associated with a Potential Offer by Walmart to acquire the outstanding shares in Massmart that it does not already own, excluding treasury shares. The Potential Offer proposes Walmart acquiring all of the outstanding shares of Massmart for a price of ZAR62 per share by way of a scheme of arrangement or a general offer if the scheme of arrangement does not become operational. This represents a premium of 53% to the closing share price and a 62% premium to the 90-day volume weighted average share price calculated at close of market on 26 August 2022. In addition, the Potential Offer presents an opportunity for minority shareholders to realise immediate value in an environment where there are no near-term catalysts for a Massmart re-rating. The Potential Offer, if finalised, will provide Massmart with needed access to ongoing financial and operational support from Walmart to sustain the Group's turnaround, which has been impeded by external factors such as Covid-19 related trading restrictions, civil unrest in KwaZulu-Natal, and a challenging economic environment. These factors have exacerbated liquidity risk at Massmart, which Walmart's financial support has helped to mitigate. This support includes a R4 billion loan provided by Walmart to Massmart at the height of the Covid-19 lockdown in April 2020, 50% of which was subsequently converted, in December 2021, into equity through a perpetual fixed rate unsecured note. The final Independent Expert report and the final views of the Massmart Independent Board will be included in a circular to be circulated to Massmart Shareholders, if a Firm Offer is made. In a move unrelated to the potential offer, Massmart has also announced CEO, Mitchell Slape's successor. Slape will step down from his role as Massmart CEO on 31 December 2022, after taking up the role in 2019. Slape will hand over to Jonathan Molapo who becomes CEO, effective 1 January 2023. Slape will remain in role until 31 December 2022 and will have ultimate responsibility to deliver the FY2022 financial plan. Reference Link

06:33 EDT BitNile subsidiary makes strategic investment in Adamas One Corp. - BitNile announced that its subsidiary, Digital Power Lending, has lent $4.1M to Adamas One Corp. in the form of a senior secured convertible note. DP Lending also received warrants to purchase shares of common stock, which are exercisable if DP Lending elects to convert the note. The Company sees this as a strategic investment to support Adamas as they seek a public listing by the end of 2022. The Company's Founder and Executive Chairman, Milton "Todd" Ault, III stated, "I am very excited to be partnering with Adamas as they explore a public offering. I believe the market for lab-grown diamonds could grow exponentially in the coming years and Adamas is well-positioned to take advantage of that growth. I look forward to supporting the company, its management and employees, and its overall operations as it grows into a leading supplier of ethically sourced diamonds."

06:16 EDT Bruker launches new nanoElute 2 nano-LC for 4D-proteomics - At the International Mass Spectrometry Conference, IMSC 2022, Bruker announced the launch of the new nanoElute 2 nano-LC, of MetaboScape and TASQ 2023 software supporting fluxomics, and of latest advances in PaSER's intelligent acquisition to enhance research in protein-protein interactions, PPIs, and metaproteomics applications. The nanoElute 2 features a further improved nano-LC pump design, and an intuitive and flexible user interface. The latest MetaboScape 2023 release provides streamlined collision cross section-enabled metabolic profiling and annotation workflows covering 4D timsTOF data acquisition to highest confidence annotations for lipids and metabolites. At IMSC, Buker also showcases the new MALDI HiPLEX-IHC workflow for multiplex imaging of protein targets. At IMSC, Bruker also further advances its bioinformatics proteomics real-time search capabilities using PaSER.

06:09 EDT Clean Energy announces new supply deals for RNG - Clean Energy Fuels (CLNE) announced new supply deals for renewable natural gas, RNG, as it forges ahead with development projects to meet the growing demand for the sustainable fuel made from organic waste. "As fleet operators of large vehicles look at the entire alternative fuel landscape, RNG continues to rise to the top as they consider carbon reduction, ease in fueling, reliability and cost," Chad Lindholm, Clean Energy's senior vice president for sales. "We continue to add new customers across all transportation sectors as they realize the benefits of RNG fueling." California Transportation Dynamics in Commerce, CA has signed a fueling agreement with Clean Energy for an approximate 1.2M gallons of RNG for the length of the contract. CTD is migrating 40 diesel trucks to units powered by RNG. National Ready Mixed Concrete in Encino, CA has signed a fueling agreement for an estimated 130,000 gallons of RNG to power 13 trucks. The City of Claremont, CA has signed a multi-year fueling agreement to power 20 refuse trucks with an anticipated 400,000 gallons of RNG. NGL Logistics in Gardena, CA has added six new natural gas trucks to its fleet that will replace diesel trucks, and will fuel with an expected 260,000 gallons of RNG. Clean Energy added a large new transit customer, Trinity Metro. Clean Energy was awarded a multi-year maintenance contract for another large new agency, Arlington Regional Transit, in Arlington, VA. Washington Metro Area Transit Authority has renewed an operations and maintenance contract with Clean Energy for its two Washington, DC area CNG stations. The City of Mesa, Arizona has signed an operations and maintenance agreement for its refuse station. The City of Lexington, KY has added seven new CNG refuse trucks to its fleet. Clean Energy has been awarded a contract to construct a fueling station for Elizabethtown Gas, a subsidiary of South Jersey Industries (SJI). Bison Trucks Group, a shipping company in Orlando, FL, has signed a fueling agreement for an approximate 224,000 gallons of natural gas to fuel 14 trucks. Howard Logistics and Solutions in Dallas has signed a fueling agreement for an approximate 105,000 gallons of CNG to power its trucks. GFL Environmental, a refuse company in Edmonton, Alberta, Canada has signed an agreement to fuel 33 trucks with an expected 1.5 million gallons of CNG. Clean Energy continues to make significant investments in the production of additional RNG sources. Construction of the RNG digester at Del Rio Dairy in Friona, TX is near completion, with commissioning of RNG flow expected to begin in Q4 2022. Significant engineering and development progress has been made at South Fork Dairy in Hart County, TX. Construction is nearing completion at Marshall Ridge, Drumgoon and Victory dairy farms, located in South Dakota and Iowa. Clean Energy has also broken ground on two additional projects. At Millenkamp Dairy in Idaho, construction is continuing with the completion of the digester tank slated for early-2023.

05:16 EDT Teva granted marketing authorization for Ranivisio by EC - Teva announced that the European Commission, or EC, has granted a marketing authorization for Ranivisio, a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentis is authorized.

05:10 EDT L&T Technology Services wins five-year infotainment deal from BMW - L&T Technology Services (LTTS) announced that it has won a five-year, multi-million-dollar deal from European luxury vehicle maker BMW (BMWYY) to provide high-end engineering services for the company's suite of infotainment consoles targeted for its family of hybrid vehicles. The LTTS team of engineers will be providing services in the areas of software build and integration, infotainment validation and defect management. LTTS has an existing Near Shore Center which provides engineering and R&D services for BMW Group's suite of infotainment consoles and its family of hybrid electric vehicles. The proximity to BMW Group's campus will enable LTTS' engineers to work on a variety of solutions and offer services in real time.

05:04 EDT Motorola awarded contract by Romanian National Administration of Penitentiaries - The Romanian National Administration of Penitentiaries has signed a contract with Motorola Solutions to deploy 2100 body-worn cameras to enhance safety and security in all prisons across the country. The new cameras will be used by prison staff during guarding activities and prisoner transport to help deter and deescalate confrontations and collect video footage in the event of conflicts or emergencies. shift, officers place their cameras into docks to automatically upload and store footage of the day's events to the VideoManager evidence management solution. For the Romanian National Administration of Penitentiaries, an agency under the Ministry of Justice, the requirements for the body-worn cameras included high resolution footage, ease of use, lightweight and rugged design, wide-angle field of view, recording storage, a battery life of up to 12 hours and the pre-recording functionality. The ability to live stream video via Wi-Fi to the control room to enhance situational awareness was also required.